HC Wainwright Reiterates “Buy” Rating for InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Friday, Marketbeat reports. They presently have a $8.00 target price on the stock.

InflaRx Price Performance

NASDAQ:IFRX opened at $1.28 on Friday. The firm has a market capitalization of $85.93 million, a price-to-earnings ratio of -1.19 and a beta of 1.98. InflaRx has a one year low of $1.13 and a one year high of $2.82. The business has a fifty day moving average price of $1.92 and a 200-day moving average price of $1.90.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. On average, equities research analysts expect that InflaRx will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

A number of institutional investors have recently bought and sold shares of IFRX. Two Sigma Securities LLC purchased a new stake in InflaRx in the 4th quarter worth $28,000. Walleye Capital LLC purchased a new stake in InflaRx in the 4th quarter worth $51,000. Cubist Systematic Strategies LLC purchased a new position in shares of InflaRx during the fourth quarter valued at about $55,000. Geode Capital Management LLC grew its position in shares of InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after purchasing an additional 11,900 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its position in shares of InflaRx by 20.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after purchasing an additional 19,000 shares in the last quarter. Hedge funds and other institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.